Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update

Q Mao, JD Unadkat - The AAPS journal, 2015 - Springer
The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-
binding cassette (ABC) efflux transporter. It was so named because it was initially cloned …

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer

K Fujita, Y Kubota, H Ishida… - World journal of …, 2015 - pmc.ncbi.nlm.nih.gov
Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a
variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of …

[HTML][HTML] Genophenotypic factors and pharmacogenomics in adverse drug reactions

R Cacabelos, V Naidoo, L Corzo, N Cacabelos… - International journal of …, 2021 - mdpi.com
Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and
illness in developed countries. ADRs show differential features depending upon genotype …

Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in …

K Kurose, E Sugiyama, Y Saito - Drug metabolism and …, 2012 - jstage.jst.go.jp
Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …

Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer

T Yoshikawa, M Sasako, S Yamamoto… - Journal of British …, 2009 - academic.oup.com
Background Locally advanced gastric cancer with extensive lymph node metastasis is
usually considered unresectable and so treated by chemotherapy. This trial explored the …

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review

JC Stingl, H Bartels, R Viviani, ML Lehmann… - Pharmacology & …, 2014 - Elsevier
UDP-glucuronosyltransferases (UGT) catalyze the biotransformation of many endobiotics
and xenobiotics, and are coded by polymorphic genes. However, knowledge about the …

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy

FC Passero Jr, D Grapsa, KN Syrigos… - Expert review of …, 2016 - Taylor & Francis
Introduction: Patients with advanced and metastatic pancreatic cancer refractory to
gemcitabine based therapy have a dismal prognosis and limited therapeutic options …

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years

M Panczyk - World Journal of Gastroenterology: WJG, 2014 - pmc.ncbi.nlm.nih.gov
During the past two decades the first sequencing of the human genome was performed
showing its high degree of inter-individual differentiation, as a result of large international …

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

M Takano, T Sugiyama - Pharmacogenomics and personalized …, 2017 - Taylor & Francis
Mutations in the UGT1A1 gene have been implicated in Gilbert syndrome, which shows mild
hyperbilirubinemia, and a more aggressive childhood subtype, Crigler–Najjar syndrome. To …

Clinically relevant genetic variations in drug metabolizing enzymes

N Pinto, M Eileen Dolan - Current drug metabolism, 2011 - ingentaconnect.com
In the field of pharmacogenetics, we currently have a few markers to guide physicians as to
the best course of therapy for patients. For the most part, these genetic variants are within a …